Erste Group Bank Analysts Boost Earnings Estimates for Amgen

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for Amgen in a report released on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will post earnings per share of $24.66 for the year, up from their prior forecast of $24.36. The consensus estimate for Amgen’s current full-year earnings is $22.94 per share.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the business earned $6.02 earnings per share. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

A number of other research analysts have also weighed in on AMGN. HSBC lowered Amgen from a “buy” rating to a “hold” rating and reduced their target price for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Barclays upped their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. TD Cowen increased their price target on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Sanford C. Bernstein raised their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Finally, Bank of America raised their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $387.93.

Amgen Stock Performance

Shares of AMGN opened at $412.84 on Wednesday. Amgen has a 52-week low of $288.00 and a 52-week high of $447.03. The stock’s 50-day simple moving average is $414.16 and its 200 day simple moving average is $373.24. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a market capitalization of $223.19 billion, a price-to-earnings ratio of 25.66, a price-to-earnings-growth ratio of 3.01 and a beta of 0.41.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Altus USA Inc. increased its stake in Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 34 shares during the last quarter. Tower View Wealth Management LLC raised its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the second quarter worth about $36,000. Evergreen Advisors LLC bought a new stake in Amgen during the first quarter worth about $37,000. Finally, Steph & Co. bought a new stake in Amgen during the third quarter worth about $42,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.